Background: Understanding how booster vaccination can prevent moderate and severe illness without hospitalization is crucial to evaluate the full advantage of mRNA boosters. Methods: We followed 85 801 participants (aged 31–81 years) in 2 large population-based cohorts during the Omicron BA.1/2 wave. Information on home testing, PCR testing, and symptoms of coronavirus disease 2019 (COVID-19) was extracted from biweekly questionnaires covering the period 12 January 2022 to 7 April 2022. Vaccination status and data on previous SARS-CoV-2 infection were obtained from national registries. Cox regression was used to estimate the effectiveness of booster vaccination compared to receipt of 2-dose primary series >130 days previously. Results: The effectiveness of booster vaccination increased with increasing severity of COVID-19 and decreased with time since booster vaccination. The effectiveness against severe COVID-19 was reduced from 80.9% shortly after booster vaccination to 63.4% in the period >90 days after vaccination. There was hardly any effect against mild COVID-19. The effectiveness tended to be lower among subjects aged ≥60 years than those aged <50 years. Conclusions: This is the first population-based study to evaluate booster effectiveness against self-reported mild, moderate, and severe COVID-19. Our findings contribute valuable information on duration of protection and thus timing of additional booster vaccinations.
The association between coronavirus disease 2019 (COVID-19) vaccination and vaginal bleeding among nonmenstruating women is not well studied. The Norwegian Institute of Public Health followed several cohorts throughout the pandemic and early performed a systematic data collection of self-reported unexpected vaginal bleeding in nonmenstruating women. Among 7725 postmenopausal women, 7148 perimenopausal women, and 7052 premenopausal women, 3.3, 14.1, and 13.1% experienced unexpected vaginal bleeding during a period of 8 to 9 months, respectively. In postmenopausal women, the risk of unexpected vaginal bleeding (i.e., postmenopausal bleeding) in the 4 weeks after COVID-19 vaccination was increased two- to threefold, compared to a prevaccination period. The corresponding risk of unexpected vaginal bleeding after vaccination was increased three- to fivefold in both nonmenstruating peri- and premenopausal women. In the premenopausal women, Spikevax was associated with at 32% increased risk as compared to Comirnaty. Our results must be confirmed in future studies.
Background: Persistent headache after SARS‐CoV‐2 infections and vaccination has been reported. However, limited data exist on the risk of new‐onset headache after these exposures compared to unexposed periods in the general population. Methods: We used data from three population‐based cohorts ( N = 85,774, age 19–81 years). SARS‐CoV‐2 infections and vaccinations were obtained from national registries and questionnaires. Before and after Omicron emergence, participants stated whether they had been suffering from headache during the past year, reported headache characteristics, and time of onset. Time‐dependent exposures were used to investigate the impact of SARS‐CoV‐2 infection and vaccination on the risk of new‐onset headache. Headache subtypes were secondary outcomes. Results: SARS‐CoV‐2 infection and first and second vaccine doses were associated with increased risk of new‐onset headache. The three cohorts, representing different age groups, were analyzed separately. For pre‐Omicron infections, the hazard ratio (HR) was 6.7 (95% confidence interval (CI) 4.8–9.2) and 6.5 (95% CI 3.8–11.1) among middle‐aged women and men, respectively. For Omicron infection, HRs were 4.7 (95% CI 4.1–5.4) and 4.5 (95% CI 3.7–5.4), respectively. The risk increased with infection severity. Corresponding HRs for first and second vaccine doses, administered during low transmission, were 1.6 and 1.7, respectively, in women, and 1.5 for both doses in men. The third dose, given before the Omicron surge, was associated with 20%–40% protection against new‐onset headache. Conclusions: SARS‐CoV‐2 infection was strongly associated with new‐onset headache. Primary vaccination was associated with a small increased risk of headache during a low‐transmission period, whereas booster vaccination offered protection during high‐transmission.